CALT - Calliditas Therapeutics AB (publ) (CALT) Q1 2024 Earnings Call Transcript
2024-05-23 15:11:04 ET
Calliditas Therapeutics AB (publ) (CALT)
Q1 2024 Earnings Conference Call
May 23, 2024 8:30 AM ET
Company Participants
Renee Aguiar-Lucander - CEO
Richard Philipson - CMO
Maria Tornsen - President, North America
Fredrik Johansson - CFO
Conference Call Participants
Zhiyao Lu - Jefferies
Vamil Divan - Guggenheim Securities
Ashiq Mubarack - Citi
Annabel Samimy - Stifel
Christopher Uhde - SEB Enskilda
Suzanne van Voorthuizen - VLK
Johan Unnerus - Redeye
Rami Katkhuda - LifeSci Capital
Erik Hultgard - Carnegie
Arthur He - HC Wainwright
Presentation
Operator
Welcome to the Calliditas Q1 2024 Report. For the first part of the conference call, the participants will be in listen-only mode. [Operator Instructions]
Now I will hand the conference over to the speakers. Please go ahead.
Renee Aguiar-Lucander
Much -- and welcome to this Q1 2024 Report from Calliditas Therapeutics. My name is Renee Aguiar-Lucander, I'm the CEO of the company, and I'm today joined by Fredrik Johansson, our Chief Financial Officer; Richard Philipson, our Chief Medical Officer; and Maria Tornsen, our President of North America.
Next page please. I would like to draw your attention to the disclaimer notice, which covers forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended and I refer to public filings, including those containing risk factors. Next page, please. So I would like to take you through some of our Q1 highlights, which included the appointment of Maria Tornsen as President of North America who brings over 10 years of rare disease experience to Calliditas including multiple product launches, both in the US and ex-US.
Following our full approval in December last year, we were able to roll out new marketing materials to a fully trained field team in February, introducing the new indication of reduction of loss of kidney function to nephrologists in the US. In February, we also announced that the USPTO had issued a new patent covering TARPEYO with exploration in 2043. In March, we could also announce that the FDA had granted a seven years of orphan exclusivity for the new indication which expires in December of 2030.
Finally, we also saw the approval in Singapore, of Nefecon, which will be known as Nefigan. Next page, please. In terms of commercial highlights for the quarter, this I want to -- from a commercial perspective as this quarter was another record quarter in terms of enrollments with 705 million new-enrollments, reflecting a 27% increase over the previous quarter in which we saw a 51% increase. This continued strong demand is very encouraging, and we continue to see strong demand for the product in the market....
Calliditas Therapeutics AB (publ) (CALT) Q1 2024 Earnings Call Transcript